Survival of Patients <= 50 Years of Age After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy
| Autoři | |
|---|---|
| Rok publikování | 2014 |
| Druh | Článek v odborném periodiku |
| Časopis / Zdroj | Canadian Journal of Cardiology |
| Fakulta / Pracoviště MU | |
| Citace | |
| Doi | http://dx.doi.org/10.1016/j.cjca.2014.03.041 |
| Obor | Kardiovaskulární nemoci včetně kardiochirurgie |
| Klíčová slova | alcohol; septal ablation; cardiomyopathy |
| Popis | Background: The long-term efficacy and safety of alcohol septal ablation (ASA) has recently been demonstrated. However, there is still debate about the outcome of younger patients who should be treated using myectomy, according to American College of Cardiology Foundation/American Heart Association guidelines. The aim of this study was to evaluate the long-term outcome of patients <= 50 years of age after ASA for hypertrophic obstructive cardiomyopathy (HOCM). Methods: We retrospectively evaluated consecutive, highly symptomatic patients aged <= 50 years with HOCM who underwent ASA. Results: Institutional databases of 3 cardiovascular centres identified 290 patients with HOCM who underwent ASA; 75 (26%) of them were aged <= 50 years at the time of their first ASA. Median duration of follow-up was 5.1 years (range, 0.1-15.4 years). Four patients (5%) died during the study period (438 patient-years; the annual mortality rate was 0.91%; 95% confidence interval [CI], 0.25-2.34%; the annual mortality rate combined with the first appropriate implantable cardioverter-defibrillator discharge was 1.43%; 95% CI, 0.52-3.10%). Survival free of all-cause mortality at 1, 5, and 10 years was 97% (95% CI, 89-99%), 94% (95% CI, 84-98%), and 94% (95% CI, 84-98%), respectively. Conclusions: Results of this first study focused on HOCM patients aged <= 50 years who underwent ASA suggest a low risk of all-cause death or appropriate implantable cardioverter-defibrillator discharge in the long-term follow-up. |